Semax and selank are both synthetic peptides developed in Russia and are frequently discussed together because they share that origin and a similar gap between established Russian clinical use and limited Western data. Semax is a synthetic ACTH analog. Selank is a synthetic tuftsin analog. Neither is FDA-approved.
At a glance
| Semax | Selank | |
|---|---|---|
| What it is | Synthetic ACTH analog studied for neuroprotective, cognitive-enhancing, and mildly anxiolytic effects | Synthetic tuftsin analog studied for anxiety reduction and cognitive enhancement, developed in Russia |
| How it's thought to work | Studied for modulating BDNF and NGF expression and enhancing serotonergic and dopaminergic neurotransmission | Studied for modulating GABA and serotonin neurotransmission and supporting immune function via tuftsin pathways |
| Regulatory status | Approved in Russia for cognitive enhancement and stroke recovery; not FDA-approved | Approved in Russia for anxiety disorders; not FDA-approved |
| Strength of evidence | Established Russian clinical use; Western clinical data is limited | Established Russian clinical use; Western clinical data is limited |
| Reported side effects | Generally well-tolerated; rare reports of irritability or overstimulation | Minimal; occasional fatigue and mild drowsiness reported |
| Common vial sizes | 5mg, 10mg | 5mg, 10mg |
| Mixing math example | 5 mg + 1 mL BAC water = 5,000 mcg/mL, 50 mcg per unit | 5 mg + 1 mL BAC water = 5,000 mcg/mL, 50 mcg per unit |
Key differences
Semax is studied for modulating BDNF and NGF expression and enhancing serotonergic and dopaminergic neurotransmission, with research describing neuroprotective effects through multiple pathways. Selank is studied for modulating GABA and serotonin neurotransmission and supporting immune function through pathways associated with tuftsin, with anxiolytic effects reported without sedation. Tuftsin itself is an immune-modulating peptide naturally present in the body, distinct from the ACTH pathway semax is built on.
Semax is approved in Russia for cognitive enhancement and stroke recovery. Selank is approved in Russia for anxiety disorders. Neither is FDA-approved, and clinical data from Western countries is described as limited for both, with most of each compound's formal clinical record coming from the Russian medical context rather than from Western trials.
Semax is generally described as well-tolerated, with rare reports of irritability or overstimulation. Selank's reported side effects are also minimal, with occasional fatigue and mild drowsiness reported.
What the research covers
Semax is approved in Russia for cognitive enhancement and for stroke recovery, with clinical data from Western countries described as limited. Selank is approved in Russia for anxiety disorders, with the same limitation on Western clinical data. Most of the formal regulatory review and clinical use for both compounds comes from the Russian medical context rather than Western trials.
Frequently asked questions
What is the difference between semax and selank?
Semax is an ACTH analog studied for neuroprotective and cognitive effects and approved in Russia for cognitive enhancement and stroke recovery. Selank is a tuftsin analog studied for anxiety reduction and approved in Russia for anxiety disorders.
Is semax or selank FDA-approved?
Neither is FDA-approved. Both are approved in Russia for their respective indications.
Which has more human research, semax or selank?
Both have an established clinical record in Russia and limited clinical data from Western countries; neither has substantial Western trial data.
Are semax and selank the same thing?
No. They are distinct molecules, an ACTH analog and a tuftsin analog respectively, studied for different primary effects despite their shared Russian origin.
Both entries, plus the calculator
The PeptidesAI app covers Semax, Selank and 68 other compounds, with a reconstitution calculator, a dose log and reminders. Free to download on iPhone.
Download on the App Store